title: Transgenic rabbits that overexpress the neonatal Fc receptor (FcRn) generate higher quantities and improved qualities of anti-thymocyte globulin (ATG).
abstract: Immune suppression with rabbit anti-thymocyte globulin (rATG) is a well-established therapeutic concept for preventing host rejection of transplanted organs and graft versus host disease. Increasing the efficiency of rATG production by reducing the number of animals would be highly beneficial to lower cost and to improve quality standards. We have developed transgenic (Tg) mice and rabbits that overexpress the neonatal Fc receptor (FcRn) and have shown an augmented humoral immune response in these animals. To test whether our FcRn Tg rabbits produced rATG more efficiently, we immunized them and their New Zealand White controls with live Jurkat cells. By day 21 after immunization, Tg animals produced significantly, 1.5 times higher amount of total IgG compared to their wt littermates. Also, the binding efficiency of Tg sera to Jurkat cells and their complement-mediated cytotoxicity was significantly higher. The purified Tg IgG preparation contained 2.6 the amount of Jurkat specific IgG as the wt preparation analyzed by complement-mediated lysis, suggesting greater antigen-specific B cell activation in the Tg rabbits. To test this hypothesis, immunization with ovalbumin and human α1-antitrypsin was performed, resulting in significantly greater numbers of antigen-specific B-cells in the FcRn Tg rabbits as compared with wt controls. The shift towards significantly larger populations of antigen-specific B cells relative to the non-specific B cell pool is further corroborated by our previous findings in FcRn Tg mice. Consequently, our FcRn Tg rabbits have the potential to offer substantial qualitative and quantitative improvements for the production of rATG and other polyclonal or monoclonal antibodies.
authors.affiliation: ImmunoGenes Kft, Budakeszi, Hungary.
authors.forename: Mária
authors.initials: M
authors.lastname: Baranyi
authors.forename: Judit
authors.initials: J
authors.lastname: Cervenak
authors.forename: Balázs
authors.initials: B
authors.lastname: Bender
authors.forename: Imre
authors.initials: I
authors.lastname: Kacskovics
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified / Q000276:immunology*; D000961:Antilymphocyte Serum / Q000096:biosynthesis* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002847:Chromatography, Agarose; D004797:Enzyme-Linked Immunosorbent Assay; D058501:Enzyme-Linked Immunospot Assay; D005434:Flow Cytometry; D006084:Graft Rejection / Q000517:prevention & control*; D015395:Histocompatibility Antigens Class I / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D019169:Jurkat Cells; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D010047:Ovalbumin / Q000494:pharmacology; D011817:Rabbits / Q000276:immunology*; D011961:Receptors, Fc / Q000276:immunology / Q000378:metabolism*; D000515:alpha 1-Antitrypsin / Q000494:pharmacology
chemical_list: D000961:Antilymphocyte Serum; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D011961:Receptors, Fc; D000515:alpha 1-Antitrypsin; D010047:Ovalbumin; C100688:Fc receptor, neonatal